无功能垂体腺瘤。
Silent corticotroph adenomas.
机构信息
Pituitary Center, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Suite A6600, Los Angeles, CA, 90048, USA,
出版信息
Pituitary. 2015 Apr;18(2):225-31. doi: 10.1007/s11102-014-0624-3.
Abstract
PURPOSE
Silent corticotroph adenomas (SCAs) comprise 20% of all corticotroph adenomas and 3-19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical or biochemical hypercortisolism, they are diagnosed after pathologic examination of resected tumor tissue demonstrates positive ACTH expression. While preoperative features are similar to those of NFAs, SCAs may have more cavernous sinus invasion. Further, patients with SCAs tend to have more frequent and earlier recurrences than those with NFAs, often necessitating multiple surgeries and other modalities of treatment. This article reviews the incidence, pathogenesis, and clinical behavior of SCAs.
METHODS
A systematic literature review was performed using PubMed for information regarding SCAs.
RESULTS
Up to date findings regarding epidemiology, pathogenesis, pathology, clinical presentation, postoperative course, and management of patients with SCAs are presented.
CONCLUSION
This review highlights the necessity of rigorous monitoring for recurrences and hypopituitarism in patients with SCAs.
摘要
目的
沉默型促肾上腺皮质激素腺瘤（SCAs）占促肾上腺皮质激素腺瘤的 20%，占无功能腺瘤的 3-19%。由于它们没有表现出临床或生化皮质醇增多症，因此在切除的肿瘤组织的病理检查显示 ACTH 表达阳性后才被诊断出来。虽然术前特征与无功能腺瘤相似，但 SCA 可能有更多的海绵窦侵犯。此外，SCA 患者比无功能腺瘤患者更频繁、更早地复发，往往需要多次手术和其他治疗方式。本文综述了 SCA 的发病率、发病机制和临床行为。
方法
使用 PubMed 进行系统的文献复习，以获取有关 SCA 的信息。
结果
目前的研究结果涉及 SCA 的流行病学、发病机制、病理学、临床表现、术后过程以及患者的管理。
结论
本文强调了对 SCA 患者进行复发和垂体功能减退监测的必要性。
相似文献
1
Silent corticotroph adenomas.无功能垂体腺瘤。
Pituitary. 2015 Apr;18(2):225-31. doi: 10.1007/s11102-014-0624-3.
2
Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.促肾上腺皮质激素细胞腺瘤无功能性复发的预测因素：一项大型回顾性单中心研究和系统文献复习。
Pituitary. 2018 Feb;21(1):32-40. doi: 10.1007/s11102-017-0844-4.
3
Silent corticotroph adenomas.无功能性促肾上腺皮质腺瘤。
Pituitary. 2018 Apr;21(2):183-193. doi: 10.1007/s11102-018-0864-8.
4
Silent Corticotroph Adenomas Demonstrate Predilection for Sphenoid Sinus, Cavernous Sinus, and Clival Invasion Compared with Other Subtypes.与其他亚型相比，沉默型促肾上腺皮质激素腺瘤更倾向于侵犯蝶窦、海绵窦和斜坡。
World Neurosurg. 2024 Nov;191:e41-e47. doi: 10.1016/j.wneu.2024.08.027. Epub 2024 Aug 21.
5
Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature.垂体促肾上腺皮质激素腺瘤中的基因和蛋白表达：文献系统综述
Neurosurg Focus. 2015 Feb;38(2):E17. doi: 10.3171/2014.10.FOCUS14683.
6
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.无功能性促肾上腺皮质激素腺瘤：临床和细胞特征及长期预后。
Horm Cancer. 2010 Apr;1(2):80-92. doi: 10.1007/s12672-010-0014-x.
7
Ectopic ACTH-secreting pituitary adenoma of the sphenoid sinus: case report of endoscopic endonasal resection and systematic review of the literature.蝶窦异位促肾上腺皮质激素分泌垂体腺瘤：经鼻内镜切除术病例报告及文献系统综述
Neurosurg Focus. 2015 Feb;38(2):E10. doi: 10.3171/2014.10.FOCUS14685.
8
Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults.成人生长激素分泌性垂体腺瘤的主要和挽救治疗的手术和非手术干预。
Cochrane Database Syst Rev. 2024 Feb 6;2(2):CD013561. doi: 10.1002/14651858.CD013561.pub2.
9
Clinical Course and Unique Features of Silent Corticotroph Adenomas.无功能性垂体腺瘤的临床病程及独特特征
World Neurosurg. 2022 May;161:e274-e281. doi: 10.1016/j.wneu.2022.01.119. Epub 2022 Feb 4.
10
Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.促肾上腺皮质激素免疫染色阳性与阴性的无功能垂体瘤的临床参数：一项对105例患者的大型回顾性单中心研究
Front Endocrinol (Lausanne). 2021 Jan 18;11:608691. doi: 10.3389/fendo.2020.608691. eCollection 2020.
引用本文的文献
1
Radiomics based on preoperative magnetic resonance imaging predict the cell lineages of nonfunctioning pituitary neuroendocrine tumors.基于术前磁共振成像的影像组学可预测无功能垂体神经内分泌肿瘤的细胞谱系。
Neuroradiology. 2025 Mar 21. doi: 10.1007/s00234-025-03593-2.
2
Radiological and Immunohistochemical Characteristics of PitNETs in 79 Patients Undergoing Neurosurgery.79例接受神经外科手术的垂体神经内分泌肿瘤的放射学和免疫组织化学特征
Cancers (Basel). 2025 Feb 16;17(4):666. doi: 10.3390/cancers17040666.
3
The 2022 WHO classification of tumors of the pituitary gland: An update on aggressive and metastatic pituitary neuroendocrine tumors.《2022年世界卫生组织垂体肿瘤分类：侵袭性和转移性垂体神经内分泌肿瘤的最新进展》
Brain Pathol. 2025 Jan;35(1):e13302. doi: 10.1111/bpa.13302. Epub 2024 Sep 1.
4
The clinicopathological features and prognosis of silent corticotroph tumors: an updated systematic review and meta-analysis.无功能促肾上腺皮质激素瘤的临床病理特征及预后：一项更新的系统评价和荟萃分析
Endocrine. 2023 Dec;82(3):527-535. doi: 10.1007/s12020-023-03449-w. Epub 2023 Jul 18.
5
Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study.囊性与非囊性无功能性促肾上腺皮质腺瘤：经蝶显微手术治疗 62 例回顾性单中心研究——临床与组织学分析
Sci Rep. 2023 Feb 11;13(1):2468. doi: 10.1038/s41598-023-29628-3.
6
Case Report: Progression of a Silent Corticotroph Tumor to an Aggressive Secreting Corticotroph Tumor, Treated by Temozolomide. Changes in the Clinic, the Pathology, and the β-Catenin and α-SMA Expression.病例报告：无功能性促肾上腺皮质激素细胞瘤进展为侵袭性分泌促肾上腺皮质激素细胞瘤，并用替莫唑胺治疗。临床、病理和β-连环蛋白及α-平滑肌肌动蛋白表达的变化。
Front Endocrinol (Lausanne). 2022 Jul 19;13:870172. doi: 10.3389/fendo.2022.870172. eCollection 2022.
7
Aggressive nonfunctioning pituitary neuroendocrine tumors.侵袭性无功能性垂体神经内分泌肿瘤。
Brain Tumor Pathol. 2022 Oct;39(4):183-199. doi: 10.1007/s10014-022-00441-6. Epub 2022 Jun 20.
8
Silent Corticotroph and Somatotroph Double Pituitary Adenoma: A Case Report and Review of Literature.沉默型促肾上腺皮质激素细胞和生长激素细胞双垂体腺瘤：一例报告并文献复习
J Neurol Surg Rep. 2022 May 27;83(2):e33-e38. doi: 10.1055/s-0042-1749389. eCollection 2022 Apr.
9
An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.沉默性促肾上腺皮质激素腺瘤的最新进展：诊断、机制、临床特征及管理
Cancers (Basel). 2021 Dec 6;13(23):6134. doi: 10.3390/cancers13236134.
10
Radiomics analysis allows for precise prediction of silent corticotroph adenoma among non-functioning pituitary adenomas.影像组学分析可精准预测无功能垂体腺瘤中的静默促肾上腺皮质激素腺瘤。
Eur Radiol. 2022 Mar;32(3):1570-1578. doi: 10.1007/s00330-021-08361-3. Epub 2021 Nov 27.
本文引用的文献
1
Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study.经立体定向放射外科治疗后的无功能促肾上腺皮质腺瘤：一项病例对照研究。
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):903-10. doi: 10.1016/j.ijrobp.2014.07.013. Epub 2014 Sep 9.
2
Silent, but not unseen: multimicrocystic aspect on T2-weighted MRI in silent corticotroph adenomas.无声却并非无形：沉默型促肾上腺皮质激素腺瘤在T2加权磁共振成像上的多微囊样表现
Clin Endocrinol (Oxf). 2014 Oct;81(4):566-72. doi: 10.1111/cen.12443. Epub 2014 May 5.
3
High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series.卡培他滨和替莫唑胺治疗促肾上腺皮质激素垂体瘤及难治性库欣病患者的高缓解率和延长生存期（CAPTEM）：病例系列
Neurosurgery. 2014 Apr;74(4):E447-55; discussion E455. doi: 10.1227/NEU.0000000000000251.
4
The role of mediators of cell invasiveness, motility, and migration in the pathogenesis of silent corticotroph adenomas.细胞侵袭、运动和迁移的介质在无功能性促肾上腺皮质腺瘤发病机制中的作用。
Endocr Pathol. 2013 Dec;24(4):191-8. doi: 10.1007/s12022-013-9270-y.
5
A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas.全面的长期回顾性分析无分泌功能的促肾上腺皮质腺瘤与激素阴性腺瘤。
Neurosurgery. 2013 Jul;73(1):8-17; discussion 17-8. doi: 10.1227/01.neu.0000429858.96652.1e.
6
Silent or Subclinical Corticotroph Pituitary Macroadenoma Transforming Into Cushing Disease: 11-Year Follow-up.沉默型或亚临床型促肾上腺皮质激素垂体大腺瘤转变为库欣病：11年随访
Neurosurgery. 2013 Jan;72(1):E144-6. doi: 10.1227/NEU.0b013e3182750850.
7
Clinical features of silent corticotroph adenomas.无功能性促肾上腺皮质激素腺瘤的临床特征。
Acta Neurochir (Wien). 2012 Aug;154(8):1493-8. doi: 10.1007/s00701-012-1378-1. Epub 2012 May 24.
8
Silent corticotroph adenomas: Emory University cohort and comparison with ACTH-negative nonfunctioning pituitary adenomas.无功能垂体腺瘤中静默促肾上腺皮质激素腺瘤：埃默里大学队列研究及与 ACTH 阴性无功能垂体腺瘤的比较。
Neurosurgery. 2012 Aug;71(2):296-303; discussion 304. doi: 10.1227/NEU.0b013e318257c1f0.
9
Anti-VEGF therapy in pituitary carcinoma.抗血管内皮生长因子治疗垂体腺癌。
Pituitary. 2012 Sep;15(3):445-9. doi: 10.1007/s11102-011-0346-8.
10
New targeted therapies in pituitary carcinoma resistant to temozolomide.对替莫唑胺耐药的垂体癌的新靶向治疗。
Pituitary. 2012 Mar;15(1):37-43. doi: 10.1007/s11102-011-0341-0.
Zotero 插件